Tag Archives: Derek Archila

Amarin (AMRN) Gets a Buy Rating from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Amarin (AMRN – Research Report). The company’s shares closed last Monday at $16.91. According to TipRanks.com, Archila is currently ranked with no stars on a

Selecta Biosciences (SELB) Receives a Buy from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELB – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $1.41, close to its 52-week low

Stifel Nicolaus Reiterates a Hold Rating on Vanda (VNDA)

In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Vanda (VNDA – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $13.14, close to its 52-week low of

Stifel Nicolaus Reaffirms Their Buy Rating on Momenta Pharma (MNTA)

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharma (MNTA – Research Report) today and set a price target of $29.00. The company’s shares closed last Monday at $14.45. According to TipRanks.com, Archila has currently no stars

AnaptysBio Inc (ANAB) Gets a Hold Rating from Stifel Nicolaus

Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on AnaptysBio Inc (ANAB – Research Report) today. The company’s shares closed last Monday at $34.99, close to its 52-week low of $34.51. According to TipRanks.com, Archila has 0 stars on

Stifel Nicolaus Keeps a Buy Rating on Urogen Pharma Ltd (URGN)

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Urogen Pharma Ltd (URGN – Research Report) yesterday and set a price target of $61. The company’s shares closed last Monday at $32.65, close to its 52-week low of $29.73.